Pomylo 1 Mg, 2 Mg, 3 Mg & 4 Mg 1 mg, 2 mg, 3 mg, 4 mg Capsule
PDF Leaflet Revision Date: June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of relapsed and refractory multiple myeloma in adults.
Dosage (summary)
Starting dose: 4 mg/day orally on Days 1-21 of 28-day cycles.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic effects expected.
Key Drug Interactions
- CYP1A2 inhibitors
- CYP3A4 inducers
- Dexamethasone
Contraindications
- Hypersensitivity
- Pregnancy
- Lactation
- Females of childbearing potential not meeting criteria
Common side effects
- Neutropenia
- Thrombocytopenia
- Fatigue
- Pneumonia
Counselling Points
- Use effective contraception
- Monitor for signs of infection
- Report any severe skin reactions
Serious warnings
- Teratogenic risk
- Venous thromboembolism
- Progressive Multifocal Leukoencephalopathy
Important Disclaimer
The Pomylo 1 Mg, 2 Mg, 3 Mg & 4 Mg 1 mg, 2 mg, 3 mg, 4 mg Capsule professional information leaflet below is the property of Forrester Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
